Administer triamcinolone with caution

Article

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration.

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration, according to the results of a study published online ahead of print by Clinical Ophthalmology.

M. Selim kocabora and co-workers from the Vakif Gureba Education and Research Hospital, Istanbul, Turkey reviewed the records of 122 patients (147 eyes) who had undergone IVTA treatment between 2003 and 2006.

The mean IOP following IVTA injection was statistically significantly higher than pre-injection IOP. Important IOP elevations were observed mostly in the first and second months. In 40 eyes (27.7%), topical anti-glaucomatous therapy was required and seven later required surgical intervention to lower IOP.

The researchers think that IVTA should be administered only after careful planning.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.